drugset
drugset / Trial / NCT04328727

Combination of Eltrombopag With Immunosuppressive Therapy in East-Asian Patients With Severe Aplastic Anemia

NCT04328727 ↗

Phase 2 Completed 36 enrolled Novartis Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

This study was designed to evaluate the efficacy and safety of eltrombopag when added to r-ATG and CsA in treatment naive East-Asian adult and pediatric patients with severe aplastic anemia (SAA).

Timeline

Start
2020-11-04
Primary completion
2022-06-10
Completion
2024-12-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Eltrombopag Small molecule 37.5 mg Oral
Subject Eltrombopag Small molecule 75 mg Oral
Background Cyclosporine Peptide 3 mg/kg Oral
Background Cyclosporine Peptide 6 mg/kg Oral
Background Thymoglobulin Protein / enzyme biologic 2.5 mg/kg Intravenous
Background Thymoglobulin Protein / enzyme biologic 3.5 mg/kg Intravenous

Indications

aplastic anemia